Electronic growth hormone injection device gains US approval
23 November 2007 Merck Serono, a division of Swiss company Merck KGaA,
has announced that its US affiliate, EMD Serono, Inc. has received US FDA
approval of its easypod delivery system for the administration of Saizen, a
treatment for growth hormone deficiency.
The device was designed to help patients administer a subcutaneous daily
injection, reliably and in just three simple key steps. A key feature of
easypod is preset dosing, which means that patients no longer have to set
their dose every day. It also tracks the number of doses administered,
allowing physicians to monitor patient adherence to therapy. It is intended
for use with Saizen click.easy cartridges after training from a healthcare
provider.
easypod is currently available in Argentina, Australia, Austria, Brazil,
Canada, Colombia, Czech Republic, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Mexico, Norway, Portugal, Slovak Republic, Spain,
Sweden, Switzerland, Turkey and the United Kingdom. The company says it will
be available in the United States soon.
To top
Save this page on del.icio.us
|